Abstract library

206 results for "Main".
#2692 Development of Ex-Vivo Models of Metastatic Neuroendocrine Neoplasms
Introduction: The lack of relevant in-vivo and in-vitro models has precluded investigations of the pathophysiology of metastatic NENs. Organotypic tumour slices retain the complexity of tumours in-vivo without extensive manipulation of the tissue.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Raj Srirajaskanthan
#2737 Identification of a Novel MAFA Missense Mutation Causing Familial Insulinomatosis
Introduction: Insulinomatosis is a rare pancreatic disease characterized by an adult-onset condition of recurrent hyperinsulinemic hypoglycemia caused by multiple insulin-secreting neuroendocrine tumors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PD. Dr. Christian Fottner
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors
Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Yuanliang Li
Authors: Li Y, Tan H, Jie C, Jie L, ...
#2691 Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study
Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: dr Sara Massironi
#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach
#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Ylenia Capodanno
#2725 Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients
Introduction: Surgery is the principal treatment for loco-regional gastroenteropancreatic (GEP) neuroendocrine tumors (NET). However, whether surgery is beneficial in high-grade neuroendocrine neoplasms (NEN) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) is not known.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Hans-Christian Pommergaard
#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling
Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr Julien Hadoux
#2783 Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours
Introduction: Prediction of progression in small intestinal neuroendocrine tumors (SI-NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Roger Belusa